Alpha Fetoprotein, CSF (Tumor Marker)
Test Mnemonic
AFPCSF
CPT Codes
- 86316 - QTY (1)
LOINC ®
1833-3
Aliases
- AFP
Includes
- Alpha Fetoprotein (CSF)
Performing Laboratory
ARUP
FDA Category
Laboratory Developed Test
Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 0.5 mL | Cerebrospinal fluid (CSF) | Sterile container | Refrigerated |
Minimum Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 0.2 mL |
Stability
| Environmental Condition | Description |
|---|---|
| Ambient | 72 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 year |
Days Performed
Sun - Sat
Turnaround Time
2 - 3 days
Methodology
| Name | Description |
|---|---|
| Chemiluminescence Immunoassay (CLIA) |
Reference Range
| AFP (CSF) | |||||
|---|---|---|---|---|---|
| Sex | Age From | Age To | Type | Range | Range Unit |
| 18 Years | 99 Years | Normal | 0 - 1 | ng/mL |
Special Info
Specimens other than CSF will be rejected. This test is New York DOH approved.
Clinical Info
The Beckman Coulter Access DXI AFP method is used. Results obtained with different assay methods or kits cannot be used interchangeably. AFP is a valuable aid in the management of nonseminomatous testicular cancer patients, when used in conjunction with information available from the clinical evaluation and other diagnostic procedures. Increased AFP concentrations have also been observed in ataxia telangiectasia, hereditary tyrosinemia, primary hepatocellular carcinoma, teratocarcinoma, gastrointestinal tract cancers with and without liver metastases, and in benign hepatic conditions such as acute viral hepatitis, chronic active hepatitis, and cirrhosis. The result cannot be interpreted as absolute evidence of the presence or absence of malignant disease. The result is not interpretable as a tumor marker in pregnant females.